Valuation: CSPC Pharmaceutical Group Limited

Market Cap 109B 13.89B 11.92B 11.19B 10.22B 19.29B 1,325B 19.38B 132B 51.33B 668B 52.16B 51.03B 2,214B P/E 2026 *
10.8x
P/E 2027 * 16x
Enterprise Value 98.08B 12.51B 10.74B 10.08B 9.21B 17.37B 1,193B 17.46B 119B 46.23B 602B 46.98B 45.96B 1,994B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.66x
Free-Float
67.42%
Yield 2026 *
4.74%
Yield 2027 * 3.8%
07:13am CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA MT
06:58am CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint MT
Aug. 24 Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy MT
Aug. 21 Bond Yields, Oil Prices Cap Asian Stock Markets MT
Aug. 21 UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50 MT
Aug. 20 Pharma sector doubles down on AI amid hopes of slashing costs, timelines RE
Aug. 20 CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Aug. 20 CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14% MT
Aug. 20 Cspc Pharmaceutical Group Limited Declares Interim Dividend for 2026, Payable on 10 November 2026 CI
Aug. 19 CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial of SYS6090 Injection for Treatment of Hepatocellular Carcinoma at First Centre in China CI
Aug. 18 CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China MT
Aug. 18 CSPC Pharmaceutical Group Limited Announces New Drug Application for Anbenitamab and Docetaxel for Injection (Albumin-Bound) for First-Line Treatment of Advanced Breast Cancer Accepted by NMPA CI
Aug. 18 Alphamab Oncology and Shanghai JMT-Bio Technology Co., Ltd. Announces Acceptance Of NDA For Anbenitamab As First-Line Treatment For HER2-Positive Advanced Breast Cancer By The NMPA CI
1 day+1.22%
1 week+8.24%
Current month+11.01%
1 month+11.40%
3 months+23.86%
6 months-4.65%
Current year+12.99%
1 week 9.02
Extreme 9.015
10.17
1 month 8.21
Extreme 8.21
10.17
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.63
10 years 3.87
Extreme 3.86979
13.93
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 44 2024-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 56 2012-01-19
Director/Board Member 66 2012-12-20
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Other

Director

-700,000 0.0061%
12/23/25 Other

Chairman

6,706,000 0.0582%
11/25/25 Other

Chairman

10,300,000 0.0894%
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+8.24%-12.21%+64.22% 13.73B
-3.21%-6.54%+62.57%+116.01% 1,100B
-1.05%-1.37%+52.80%+64.14% 658B
-1.47%-1.65%+25.55%+77.43% 470B
-1.47%+0.24%+42.09%+42.12% 372B
-0.90%+0.05%+25.57%+40.59% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.38%-0.33%+52.25%+71.86% 239B
-0.93%+1.84%-13.11%-52.83% 213B
-0.10%+0.70%+29.53%+92.94% 184B
Average -0.98%+3.40%+26.81%+52.97% 381.66B
Weighted average by Cap. -1.68%+2.23%+40.55%+68.55%

Financials

2026 *2027 *
Net sales 38.62B 4.93B 4.23B 3.97B 3.63B 6.84B 470B 6.87B 46.97B 18.2B 237B 18.5B 18.1B 785B 35.63B 4.55B 3.9B 3.66B 3.34B 6.31B 434B 6.34B 43.33B 16.79B 219B 17.07B 16.7B 724B
Net income 10.12B 1.29B 1.11B 1.04B 950M 1.79B 123B 1.8B 12.31B 4.77B 62.13B 4.85B 4.74B 206B 6.98B 891M 764M 718M 655M 1.24B 84.95B 1.24B 8.49B 3.29B 42.86B 3.34B 3.27B 142B
Net Debt -10.82B -1.38B -1.18B -1.11B -1.02B -1.92B -132B -1.93B -13.15B -5.1B -66.39B -5.18B -5.07B -220B -14.06B -1.79B -1.54B -1.44B -1.32B -2.49B -171B -2.5B -17.1B -6.63B -86.3B -6.73B -6.59B -286B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
18,626
Date Price Change Volume
26-08-26 HK$9.525 +1.22% 190,279,844
26-08-25 HK$9.410 +0.16% 126,608,259
26-08-24 HK$9.395 +2.23% 141,570,805
26-08-21 HK$9.190 -3.47% 135,368,018
26-08-20 HK$9.520 +9.61% 439,742,523
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
9.525HKD
Average target price
12.44HKD
Spread / Average Target
+30.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock